News & Updates

A 12-week lifestyle intervention comprising a moderate-intensity physical activity (PA) programme and a hypocaloric Mediterranean diet (MD) promoted fat removal and liver fibrosis improvement in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), findings from the EHmet-DIA study suggest.

An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.

A study presented at DDW 2024 showed that adequate physical activity reduces the risk of cirrhosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

An exosome-based liquid biopsy showed favourable signals for noninvasive, early detection of pancreatic ductal adenocarcinoma (PDAC) in a prospective study.

An investigational blood-based test performs satisfactorily for the early detection of colorectal cancer (CRC), having met all prespecified primary endpoints in the large PREEMPT CRC trial.

Patients with inflammatory bowel disease (IBD) who use statins appear to have a substantially reduced risk of primary sclerosing cholangitis (PSC), as shown in a retrospective study.